Glenmark to begin clinical trial in India to test Covid-19 drug combination

Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs, favipiravir and umifenovir, as a potential Covid-19 treatment.

The study will look to enroll 158 hospitalized patients suffering from moderate Covid-19 infections in India, the company said, the Reuters reported.

Drugmakers across the world have been rushing to develop a treatment or vaccine for the fast-spreading coronavirus, which has infected 5.5 million people globally, killing more than 345,000.

In India, now among the 10 most affected nations, the death toll from Covid-19 reached 4,167 on Tuesday.